“…For the past decades, the perspective that neovascularization in the early phase is pivotal in improving adipocyte survival rate has been widely accepted [16][17][18]. Thereby, all kinds of growth factors, e.g., VEGF, bFGF, IGF-1, HGF, EGF, etc., have been explored hoping to reduce the absorbance and most of them achieved satisfying results [19][20][21][22][23][24]. Due to the fact that most of these factors are susceptible, expensive, require a carrier and, most serious of all, are linked to tumor risks [25][26][27][28][29][30][31], clinical use is strongly restricted and limited.…”